Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.36 |
| ▸ | FEN1 | P39748 | 3/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19501588 | 0.92 | PTGDR2 (0.37) | PTGDR2ALOX5APFEN1DDR1PTGS2 | |
| SCHEMBL19523575 | 0.89 | DDR1 (0.33) | DDR1 | |
| SCHEMBL17664488 | 0.87 | PTGDR2 (0.39) | PTGDR2ALOX5APFEN1DDR1SCN9A | |
| SCHEMBL19501589 | 0.87 | PTGDR2 (0.36) | PTGDR2ALOX5APFEN1DDR1PTGS2 | |
| SCHEMBL17664455 | 0.86 | PTGDR2 (0.34) | PTGDR2ALOX5APFEN1DDR1PTGS2 | |
| SCHEMBL19522228 | 0.81 | DDR1 (0.34) | PTGDR2DDR1PTGS2 | |
| SCHEMBL17664475 | 0.80 | ALOX5AP (0.37) | PTGDR2ALOX5APFEN1DDR1 | |
| SCHEMBL19501585 | 0.78 | PTGDR2 (0.39) | PTGDR2ALOX5APFEN1DDR1SCN9A | |
| SCHEMBL19522227 | 0.76 | DDR1 (0.32) | DDR1 | |
| SCHEMBL19523564 | 0.76 | DDR1 (0.32) | DDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3202762-B1 | PYRIMIDINONE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2019-06-19 | — | — | EP | disclosed |
| US-20170305896-A1 | PYRIMIDINONE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-26 | — | — | US | disclosed |
| EP-3202762-A1 | PYRIMIDINONE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2017-08-09 | — | — | EP | disclosed |
| WO-2017090654-A1 | PEST CONTROL COMPOSITION AND USE THEREOF | 住友化学株式会社 | 2017-06-01 | — | — | WO | disclosed |
| WO-2016052247-A1 | PYRIMIDINONE COMPOUND | 住友化学株式会社 | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305896-A1 | PYRIMIDINONE COMPOUND | C5, C3AR1, CCR3 | PTGDR2 1449/4885ALOX5AP 4279/4885FEN1 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.